Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The close medium term support offers good timing for purchasing the stock.
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 32.42 USD
Weaknesses
  • The company has insufficient levels of profitability.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
ADAPTIVE BIOTECHNOLOGIES CO..53.18%6 268
EXACT SCIENCES CORPORATION25.29%18 427
GUARDANT HEALTH, INC.44.15%11 261
INVITAE CORPORATION190.45%8 278
IOVANCE BIOTHERAPEUTICS, IN..37.07%5 565
-
SEEGENE INC--.--%4 255
VERACYTE, INC.82.31%2 947
CAREDX, INC159.99%2 762
Q-LINEA AB (PUBL)190.43%529
BIOVICA INTERNATIONAL AB (P..244.07%135
EPIGENOMICS AG-66.81%25
More Results
Financials (USD)
Sales 2020 94,8 M - -
Net income 2020 -142 M - -
Net cash 2020 509 M - -
P/E ratio 2020 -43,4x
Yield 2020 -
Capitalization 6 268 M 6 268 M -
EV / Sales 2020 60,7x
EV / Sales 2021 36,0x
Nbr of Employees 453
Free-Float 94,2%
Upcoming event on ADAPTIVE BIOTECHNOLOGIES CORPORATION
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality -
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes